A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders (GDKet)
A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders: Gdansk Depression Ketamine Project
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Maria Gałuszko-Węgielnik, MD PhD
- Phone Number: +48 58 3492650
- Email: mgaluszko@gumed.edu.pl
Study Contact Backup
- Name: Wiesław J. Cubała, MD PhD
- Phone Number: +48 58 3492650
- Email: cubala@gumed.edu.pl
Study Locations
-
-
-
Gdańsk, Poland, 80-952
- Department of Psychiatry, Medical University of Gdańsk
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Major depressive disorder (MDD) or bipolar disorder (BD) diagnosis as provided by DSM-5 criteria
- TRD defined as the patient does not reach remission within the 8 week trial of an antidepressant or combination at a therapeutic dose of at least two trials of first-line evidence-based treatments and/or electroconvulsive therapy (ECT)
Exclusion Criteria:
- Pregnancy and lactation
- Hypersensitivity to ketamine
- Uncontrolled hypertension
- Other uncontrolled somatic diseases that may impact safety per investigators judgement
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Incidence of adverse events assessed by Clinical-Administered Dissociative Symptoms Scale (CADSS)
Time Frame: Baseline through week 5
|
Incidence of adverse events will be assessed by Clinician-Administered Dissociative Symptoms Scale (change from baseline to each measure).
Higher values represent a worse severity, but not necessarily outcome.
The Clinical-Administered Dissociative Symptoms Scale has 23-items based on dissociative symptoms during the assessment.
Each item is scored 0 (normal) to 4 (severe symptoms) with overall score ranges from 0 (normal) to 92 (severe symptoms).
Total number of assessments:18 times
|
Baseline through week 5
|
|
Incidence of adverse events assessed by body temperature (oral measurements)
Time Frame: Baseline through week 5
|
Incidence of adverse events assessed by body temperature (oral measurement) in Celsius degree - change from baseline to each measure.
A normal range is from 36.2 to 38.0 Celsius degrees; measurements beyond those ranges are clinically significant.
The total number of measurements: 44 times
|
Baseline through week 5
|
|
Incidence of adverse events assessed by respiration rate
Time Frame: Baseline through week 5
|
Incidence of adverse events assessed by respiration rate in a breath number per minute - change from baseline to each measure.
A normal range for respiration is from 12 to 16 breaths per minute; measurements beyond those ranges are clinically significant.
The total number of measurements: 44 times
|
Baseline through week 5
|
|
Incidence of adverse events assessed by pulse
Time Frame: Baseline through week 5
|
Incidence of adverse events assessed by pulse (beats per minute [bpm]) - change from baseline to each measure.
A normal range for pulse is from 60 to 90 bpm; measurements beyond those ranges are clinically significant.
The total number of measurements: 44 times
|
Baseline through week 5
|
|
Incidence of adverse events assessed by blood oxygen saturation
Time Frame: Baseline through week 5
|
Incidence of adverse events assessed by blood oxygen saturation in percentage - change from baseline to each measure.
A normal range for blood oxygen saturation is from 95 to 100 percentage; measurements under 95% are clinically significant.
The total number of measurements: 44 times
|
Baseline through week 5
|
|
Incidence of adverse events assessed by 4-items positive symptoms subscale of Brief Psychiatric Rating Scale (BPRS)
Time Frame: Baseline through week 5
|
Incidence of adverse events will be assessed by 4-items positive symptoms subscale of Brief Psychiatric Rating Scale (change from baseline to each measure).
Higher values represent a worse severity but not necessarily outcome.
The 4-item positive symptoms subscale of Brief Psychiatric Rating Scale has 4-items based on conceptual disorganization, suspiciousness, hallucination and unusual thought content.
Each item is scored 0 (normal) to 6 (severe symptoms) with overall score ranges from 0 (normal) to 24 (severe symptoms).
Total number of assessments:18 times
|
Baseline through week 5
|
|
Incidence of adverse events assessed by blood pressure
Time Frame: Baseline through week 5
|
Incidence of adverse events assessed by blood pressure (after the participant has rested for at least 5 minutes) in mmHg - change from baseline to each measure.
A normal range for systolic blood pressure is from 90 to 140 mmHg, for diastolic blood pressure is from 50 to 90 mmHg; measurements beyond those ranges are clinically significant.
The total number of measurements: 44 times
|
Baseline through week 5
|
|
Incidence of adverse events assessed by weight
Time Frame: Baseline and week 5
|
Incidence of adverse events assessed by weight in kilograms- change from baseline to each measure.
Gain weight for 7% baseline weight is clinically significant.
Total numbers of assessments: 2. Weight and height will be combined to report BMI in kg/m^2
|
Baseline and week 5
|
|
Incidence of adverse events assessed by height
Time Frame: Baseline
|
Incidence of adverse events assessed by height in meters.
Total numbers of assessments: 1. Weight in kilograms and height in meters will be combined to report BMI in kg/m^2
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in severity of depression symptoms assessed by Montgomery-Asberg Depression Rating Scale (MADRS)
Time Frame: Baseline through week 5
|
Change in severity of depression symptoms from baseline to each measure.
Higher values represent a worse severity, but not necessarily outcome.
The MADRS has 10-items which are based on mood symptoms over the past 7 days.
Each item is scored 0 (normal) to 6 (severe depression) with overall score ranges from 0 (normal) to 60 (severe depression).
|
Baseline through week 5
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Wlodarczyk A, Cubala WJ, Galuszko-Wegielnik M, Szarmach J. Dissociative symptoms with intravenous ketamine in treatment-resistant depression exploratory observational study. Medicine (Baltimore). 2021 Jul 23;100(29):e26769. doi: 10.1097/MD.0000000000026769.
- Wlodarczyk A, Cubala WJ, Galuszko-Wegielnik M, Szarmach J. Central nervous system-related safety and tolerability of add-on ketamine to antidepressant medication in treatment-resistant depression: focus on the unique safety profile of bipolar depression. Ther Adv Psychopharmacol. 2021 May 19;11:20451253211011021. doi: 10.1177/20451253211011021. eCollection 2021.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Bipolar and Related Disorders
- Depression
- Depressive Disorder
- Bipolar Disorder
- Mood Disorders
- Depressive Disorder, Major
- Depressive Disorder, Treatment-Resistant
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Ketamine
Other Study ID Numbers
Other Study ID Numbers
- NKBBN/172-674/2019
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.